Diabetes, Vol 49, Issue 9 1419-1426, Copyright © 2000 by American Diabetes Association

ARTICLES

Molecular mode of inhibition of glycogenolysis in rat liver by the dihydropyridine derivative, BAY R3401: inhibition and inactivation of glycogen phosphorylase by an activated metabolite

N Bergans, W Stalmans, S Goldmann and F Vanstapel
Department of Radiology, Faculty of Medicine, Katholieke Universiteit Leuven, Belgium.

The racemic prodrug BAY R3401 suppresses hepatic glycogenolysis. BAY W1807, the active metabolite of BAY R3401, inhibits muscle glycogen phosphorylase a and b. We investigated whether BAY R3401 reduces hepatic glycogenolysis by allosteric inhibition or by phosphatase-catalyzed inactivation of phosphorylase. In gel-filtered liver extracts, racemic BAY U6751 (containing active BAY W1807) was tested for inhibition of phosphorylase in the glycogenolytic (in which only phosphorylase a is active) and glycogen-synthetic (for the evaluation of a:b ratios) directions. Phosphorylase inactivation by endogenous phosphatase was also studied. In liver extracts, BAY U6751 (0.9-36 micromol/l) inhibited glycogen synthesis by phosphorylase b (notwithstanding the inclusion of AMP), but not by phosphorylase a. Inhibition of phosphorylase-a-catalyzed glycogenolysis was partially relieved by AMP (500 micromol/l). BAY U6751 facilitated phosphorylase-a dephosphorylation. Isolated hepatocytes and perfused livers were tested for BAY R3401-induced changes in phosphorylase-a:b ratios and glycogenolytic output. Though ineffective in extracts, BAY R3401 (0.25 micromol/l-0.5 mmol/l) promoted phosphorylase-a dephosphorylation in hepatocytes. In perfused livers exposed to dibutyryl cAMP (100 micromol/l) for maximal activation of phosphorylase, BAY R3401 (125 micromol/l) inactivated phosphorylase by 63% but glucose output dropped by 83%. Inhibition of glycogenolysis suppressed glucose-6-phosphate (G6P) levels. Activation of glycogen synthase after phosphorylase inactivation depended on the maintenance of G6P levels by supplementing glucose (50 mmol/l). We conclude that the metabolites of BAY R3401 suppress hepatic glycogenolysis by allosteric inhibition and by the dephosphorylation of phosphorylase a.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Z. Gregus and B. Nemeti Glutathione-Dependent Reduction of Arsenate by Glycogen Phosphorylase Responsiveness to Endogenous and Xenobiotic Inhibitors Toxicol. Sci., November 1, 2007; 100(1): 44 - 53. [Abstract] [Full Text] [PDF]

				L. J. Hampson and L. Agius Increased Potency and Efficacy of Combined Phosphorylase Inactivation and Glucokinase Activation in Control of Hepatocyte Glycogen Metabolism Diabetes, March 1, 2005; 54(3): 617 - 623. [Abstract] [Full Text] [PDF]

				A. R. Green, S. Aiston, C. C. Greenberg, S. Freeman, S. M. Poucher, M. J. Brady, and L. Agius The Glycogenic Action of Protein Targeting to Glycogen in Hepatocytes Involves Multiple Mechanisms Including Phosphorylase Inactivation and Glycogen Synthase Translocation J. Biol. Chem., November 5, 2004; 279(45): 46474 - 46482. [Abstract] [Full Text] [PDF]

				D. S. Edgerton, S. Cardin, D. Neal, B. Farmer, M. Lautz, C. Pan, and A. D. Cherrington Effects of hyperglycemia on hepatic gluconeogenic flux during glycogen phosphorylase inhibition in the conscious dog Am J Physiol Endocrinol Metab, April 1, 2004; 286(4): E510 - E522. [Abstract] [Full Text] [PDF]

				S. Aiston, B. Andersen, and L. Agius Glucose 6-Phosphate Regulates Hepatic Glycogenolysis Through Inactivation of Phosphorylase Diabetes, June 1, 2003; 52(6): 1333 - 1339. [Abstract] [Full Text] [PDF]

				R. R. Gomis, C. Favre, M. Garcia-Rocha, J. M. Fernandez-Novell, J. C. Ferrer, and J. J. Guinovart Glucose 6-Phosphate Produced by Gluconeogenesis and by Glucokinase Is Equally Effective in Activating Hepatic Glycogen Synthase J. Biol. Chem., March 7, 2003; 278(11): 9740 - 9746. [Abstract] [Full Text] [PDF]

				D. S. Edgerton, S. Cardin, C. Pan, D. Neal, B. Farmer, M. Converse, and A. D. Cherrington. Effects of Insulin Deficiency or Excess on Hepatic Gluconeogenic Flux During Glycogenolytic Inhibition in the Conscious Dog Diabetes, November 1, 2002; 51(11): 3151 - 3162. [Abstract] [Full Text] [PDF]

				K. Igawa, M. Mugavero, M. Shiota, D. W. Neal, and A. D. Cherrington Insulin Sensitively Controls the Glucagon Response to Mild Hypoglycemia in the Dog Diabetes, October 1, 2002; 51(10): 3033 - 3042. [Abstract] [Full Text] [PDF]

				K. Fosgerau, J. Breinholt, J. G. McCormack, and N. Westergaard Evidence against Glycogen Cycling of Gluconeogenic Substrates in Various Liver Preparations J. Biol. Chem., August 2, 2002; 277(32): 28648 - 28655. [Abstract] [Full Text] [PDF]

				L. A. Hornbuckle, D. S. Edgerton, J. E. Ayala, C. A. Svitek, J. K. Oeser, D. W. Neal, S. Cardin, A. D. Cherrington, and R. M. O'Brien Selective tonic inhibition of G-6-Pase catalytic subunit, but not G-6-P transporter, gene expression by insulin in vivo Am J Physiol Endocrinol Metab, October 1, 2001; 281(4): E713 - E725. [Abstract] [Full Text] [PDF]

				B. R. Landau Methods for measuring glycogen cycling Am J Physiol Endocrinol Metab, September 1, 2001; 281(3): E413 - E419. [Abstract] [Full Text] [PDF]

				K. Fosgerau, S. D. Mittelman, A. Sunehag, M. K. Dea, K. Lundgren, and R. N. Bergman Lack of hepatic "interregulation" during inhibition of glycogenolysis in a canine model Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E375 - E383. [Abstract] [Full Text] [PDF]

				S. Cardin, P. A. Jackson, D. S. Edgerton, D. W. Neal, C. S. Coffey, and A. D. Cherrington Effect of Vagal Cooling on the Counterregulatory Response to Hypoglycemia Induced by a Low Dose of Insulin in the Conscious Dog Diabetes, March 1, 2001; 50(3): 558 - 564. [Abstract] [Full Text]

				S. Aiston, L. Hampson, A. M. Gomez-Foix, J. J. Guinovart, and L. Agius Hepatic Glycogen Synthesis Is Highly Sensitive to Phosphorylase Activity. EVIDENCE FROM METABOLIC CONTROL ANALYSIS J. Biol. Chem., June 22, 2001; 276(26): 23858 - 23866. [Abstract] [Full Text] [PDF]